Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

202339 citationsJournal Articlegold Open Access

Authors

Taito Fukushima · Kanagawa Prefectural Hospital Organization

Manabu Morimoto · Kanagawa Cancer Center

Satoshi Kobayashi · Kanagawa Cancer Center

Makoto Ueno · Kanagawa Cancer Center

Haruki Uojima · Kitasato University

Hisashi Hidaka · Kitasato University

Chika Kusano ·

Abstract

The development of irAEs was associated with increased survival in a real-world population of patients with advanced HCC treated with atezolizumab plus bevacizumab. Grade 1/2 irAEs were strongly correlated with PFS and OS.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Hepatocellular Carcinoma Treatment and Prognosis Ferroptosis and cancer prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 28, Issue 7, pp. e526-e533

DOI: 10.1093/oncolo/oyad090

Field-Weighted Citation Impact: 9.17

Command Palette